公开(公告)号：AT435214T

公开(公告)日：2009-07-15

申请号：AT05807734

申请日：2005-08-31

Applicant: VERTEX PHARMA

Inventor： WILSON DEAN ,  TERMIN ANDREAS ,  GONZALEZ JESUS ,  FANNING LEV ,  NEUBERT TIMOTHY ,  KRENITSKY PAUL ,  JOSHI PRAMOD ,  HURLEY DENNIS ,  SHETH URVI ,  BOGER JOSHUA

IPC: C07D239/94 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12

Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

公开(公告)号：DE69127970T2

公开(公告)日：1998-03-05

申请号：DE69127970

申请日：1991-07-02

Applicant: VERTEX PHARMA

Inventor： ARMISTEAD DAVID ,  BOGER JOSHUA ,  MEYERS HAROLD ,  SAUNDERS JEFFREY ,  TUNG ROGER

IPC: A61K31/34 ,  A61K31/16 ,  A61K31/165 ,  A61K31/341 ,  A61K31/343 ,  A61K31/357 ,  A61K31/36 ,  A61K31/38 ,  A61K31/381 ,  A61K31/395 ,  A61K31/40 ,  A61K31/401 ,  A61K31/4025 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/4525 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  A61P25/02 ,  A61P37/06 ,  C07C233/56 ,  C07C235/12 ,  C07C235/34 ,  C07D207/08 ,  C07D207/16 ,  C07D211/60 ,  C07D307/54 ,  C07D317/60 ,  C07D333/24 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06 ,  C07C235/72 ,  A61K31/215 ,  A61K31/335

Abstract: This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.

公开(公告)号：DE69127970D1

公开(公告)日：1997-11-20

申请号：DE69127970

申请日：1991-07-02

Applicant: VERTEX PHARMA

Inventor： ARMISTEAD DAVID ,  BOGER JOSHUA ,  MEYERS HAROLD ,  SAUNDERS JEFFREY ,  TUNG ROGER

IPC: A61K31/34 ,  A61K31/16 ,  A61K31/165 ,  A61K31/341 ,  A61K31/343 ,  A61K31/357 ,  A61K31/36 ,  A61K31/38 ,  A61K31/381 ,  A61K31/395 ,  A61K31/40 ,  A61K31/401 ,  A61K31/4025 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/4525 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  A61P25/02 ,  A61P37/06 ,  C07C233/56 ,  C07C235/12 ,  C07C235/34 ,  C07D207/08 ,  C07D207/16 ,  C07D211/60 ,  C07D307/54 ,  C07D317/60 ,  C07D333/24 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06 ,  C07C235/72 ,  A61K31/215 ,  A61K31/335

Abstract: This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.